XVIVO Perfusion – Consensus estimates Q2 2026
2026-07-09 12:30:00
Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.
Number of contributors: 7 (all of which have been updated or confirmed before the report)
| KPI (MSEK, unless otherwise specified) | Q2 2026E |
| Net sales | 234 |
| Organic growth in local currency (%) | 33.58 |
| Gross profit | 170 |
| EBITDA | 47.9 |
| EBIT | 28.0 |
| Net profit | 21.9 |
| Earnings per share (SEK) | 0.70 |
XVIVO Perfusion’s Q2 report will be released on Tuesday 14 July at 07.30 CEST.